The Life Sciences team advised Ollin Biosciences on its launch with an initial $100 million in financing led by ARCH Venture Partners, Mubadala Capital and Monograph Capital. Ollin is assembling a robust pipeline of both clinical and late-stage preclinical programs, building upon validated biologies to better address unmet treatment needs in ophthalmology.
Additionally, Goodwin advised on Ollin's collaboration with Innovent Biologics to develop OLN324. The drug is a bispecific antibody that blocks a pair of proteins, VEGF and Ang2, involved in the progression of age-related macular degeneration and diabetic macular edema.
Established in 2023, Ollin BiosciencesTM is a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. With a differentiated pipeline, world-class team, and strong investor syndicate, Ollin is redefining what’s possible in ophthalmology.
The Goodwin corporate team was led by Maggie Wong, Theo Haboucha, Kingsley Taft and included Swetha Gopalakrishnan, Ashley Shultz and Ruowen Li. The licensing team was led by Sarah Stoiber, Christopher Zhong, Alexandra Haas, and Kingsley Taft and included Elizabeth Mulkey.
For more information on the deal, please read the press release and coverage in BioPharma Dive and Endpoints News.